Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Otologic Pharmaceutics Inc.
DescriptionFixed-dose combination of HPN-07, a free radical trapping agent, and N-acetylcysteine (NAC)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHearing loss
Indication DetailsTreat acute sensorineural hearing loss; Treat cisplatin induced hearing loss
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today